Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/12/2023 | $30.00 → $3.00 | Buy → Hold | Canaccord Genuity |
| 2/18/2022 | $20.00 | Overweight | Cantor Fitzgerald |
| 11/30/2021 | $17.00 → $32.00 | Buy | HC Wainwright & Co. |
| 11/29/2021 | $17.00 → $32.00 | Buy | HC Wainwright & Co. |
| 11/2/2021 | $20.00 → $35.00 | Buy | Aegis Capital |
| 7/29/2021 | $27.00 → $30.00 | Buy | Canaccord Genuity |
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials.Distribution of majority of Oramed's holding in OraTech to Oramed shareholders via dividend planned to coincide with OraTech's public listing.Cash dividend planned (~$0.25 per share).Marketing Authorization Application has been submitted by HTIT, and commercialization preparations are underway for oral insulin capsule. OraTech expected to receive royalties from sales in China.Oramed to receive royalty streams over the next decade from multiple Scilex products including $400,000 due for Q4 2024 sales.NEW YORK, March 4, 2025 /
NEW YORK, May 25, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following Letter to Shareholders from Chief Executive Officer Nadav Kidron. Dear Shareholders, I'm excited to share with you significant milestones we have achieved over the past few months. Our oral delivery platform technology could apply to a range of proteins and disease modalities, and we expect over time to have a range of programs. We are currently advancing our two primary programs: oral insulin for diabetes and an oral COVID vaccine. We believe t
8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
10-Q - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
NEW YORK, May 1, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the "Company") (www.oramed.com) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023. The Board determined that Mr. Shapiro qualifies as an independent director under the listing rules of the Nasdaq Capital Market. Ben Shapiro is a successful entrepreneur and business professional who co-founded The Daily Wire, a successful, industry leading, international media outlet in June 2015. Since May 2015, he is host of "The Ben Shapiro Show," a popular podcast, and he is the author of numerous New York Times best-selling books. Mr. Shapiro earned
NEW YORK, June 1, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board. Anne Peters, MD, is Professor of Medicine at the Keck School of Medicine of USC and Director of the USC Clinical Diabetes Programs. Dr. Peters earned her medical degree from the Pritzker School of Medicine at the University of Chicago and performed an internal medicine residency at Stanford University and an endocrinology fellowship at Cedars-Sinai Medical Center. She previously directed the clinical diabetes progra
NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, effective January 9, 2022. Mr. Derovan will oversee Oramed's legal and corporate strategy affairs and provide strategic guidance to the executive team and Board of Directors. "We are very pleased to welcome Netanel Derovan as Oramed's Chief Legal Officer. Netanel's business-minded approach, legal acumen and strong operational skills will be instrumental to Oramed
SC 13G - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)
SC 13D - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)
SC 13D/A - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)
Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology NEW YORK, April 28, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (NASDAQ:ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that
JERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that it has successfully closed a registered direct offering (the "offering") whereby an affiliate of Oramed Pharmaceuticals Inc. ("Oramed") (NASDAQ:ORMP) (TASE: ORMP) purchased 14,110,121 of Alpha Tau's ordinary shares, no par value, at a purchase price of $2.612 per ordinary share. The offering closed on April 28, 2025. The total gross proceeds of the offering were approximately $36.9 million, before deducting estimated offering expenses payable by Alpha Tau. Alpha Tau int
Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. - A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials.Distribution of majority of Oramed's holding in OraTech to Oramed shareholders via dividend planned to coincide with OraTech's public listing.Cash dividend planned (~$0.25 per share).Marketing Authorization Application has been submitted by HTIT, and commercialization preparations are underway for oral insulin capsule. OraTech expected to receive royalties from sales in China.Oramed to receive royalty streams over the next decade from multiple Scilex products including $400,000 due for Q4 2024 sales.NEW YORK, March 4, 2025 /
Canaccord Genuity downgraded Oramed Pharmaceuticals from Buy to Hold and set a new price target of $3.00 from $30.00 previously
Cantor Fitzgerald initiated coverage of Oramed Pharmaceuticals with a rating of Overweight and set a new price target of $20.00
HC Wainwright & Co. reiterated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $17.00 previously